GSK plc's new prefilled syringe presentation of Shingrix was accepted for review by the EMA on January 27, 2025; if approved, it will simplify administration for healthcare professionals. Over 25 million people in Europe have received Shingrix since 2018—this comes after its FDA acceptance on January 8, 2025.